Mainstay Medical is thrilled to announce an exciting new milestone in its journey to transform chronic low back pain treatment—a remarkable funding round that raised $100 million. This significant capital infusion comes at a pivotal time for the company, whose groundbreaking innovation, ReActiv8®, stands as the first and only FDA-approved restorative treatment for mechanical chronic low back pain. Led by a highly dedicated team of scientists, executives, engineers, and clinical experts, Mainstay Medical is poised to further enhance its mission of improving patient lives and driving global health innovation. With a history rooted in innovation and excellence, the company was incorporated in Dublin, Ireland, and now calls San Diego, CA its headquarters, with a robust network of subsidiaries spanning Ireland, the United States, Australia, Germany, and the Netherlands.
The new funding will be strategically deployed to accelerate the development and broader deployment of the ReActiv8® system, empowering patients to regain control over their lives. This investment will support initiatives that enhance core product features such as RESTORE Control, RESTORE Function, and RESTORE Stability, as well as expand the reach of the ReActiv8 LIFE program—a comprehensive solution designed to optimize long-term treatment outcomes. With this new capital backing, Mainstay Medical is set to accelerate research, expand clinical trials, and enhance patient support and service networks globally. The company remains steadfast in its commitment to revolutionize the way chronic low back pain is understood and treated, ensuring that every step taken is a stride towards a better, pain-free future for patients worldwide.
